Single ChAdOx1 nCoV ‐19 dose elicits stronger immune response in previously infected individuals than in SARS‐CoV2 naive persons

ConclusionsPrevious COVID-19 infection is associated with higher levels of SARS-CoV-2 antibodies following ChAdOx1 (AstraZeneca) vaccination. Our finding supports the notion that a single dose of ChAdOx1 nCoV-19 administered post-SARS-CoV-2 infection serves as an effective immune booster. This provides a possible rationale for a single-dose vaccine regimen for previously infected individuals.

Source: Immunity, Inflammation and Disease - January 19, 2024 Category: Allergy & Immunology Authors: Fawzi Ebrahim, Asma Alboueishi, Inas M. Alhudiri, Salah Al Tabal, Yosra Lamami, Samira Al Dwigen, Sondos Ashleb, Noha Ejenfawi, Mohamed B. Milad, Hayat Rhoumah, Salah Edin El Meshri, Adam Elzagheid Tags: ORIGINAL ARTICLE Source Type: research